Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.
about
Fertility and pregnancy in rheumatoid arthritis and systemic lupus erythematosus.Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis.Pregnancy and lupus nephritis.Effect of Previous Chemotherapy on the Quality of Cryopreserved Human Ovarian Tissue In Vitro.Cyclophosphamide: new approaches for systemic lupus erythematosus.Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: Results from a case control study and literature review.Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility.Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the GOAL study.Age- and sex-related patterns of serum interferon-alpha activity in lupus families.Treatment of systemic lupus erythematosus: new advances in targeted therapy.Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network.Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.Menopause and Rheumatic Disease.Infertility - Prevention and Management.Prevalence of premature ovarian failure in patients with systemic lupus erythematosus.Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand.Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.Ameliorative Effect of Gallic Acid on Cyclophosphamide-Induced Oxidative Injury and Hepatic Dysfunction in Rats.The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.Risk factors for ovarian failure in patients with systemic lupus erythematosus.Testicular gametogenic and steroidogenic activities in cyclophosphamide treated rat: a correlative study with testicular oxidative stress.Infertility today: the management of female medical causes.Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.Menstrual and hormonal alterations in juvenile systemic lupus erythematosus.Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus.Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].Minimal residual disease of leukemia and the quality of cryopreserved human ovarian tissue in vitro.Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients.Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.Reproductive health in women with systemic lupus erythematosus compared to population controls.Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study.Ameliorative effect of propolis against cyclophosphamide-induced toxicity in mice.Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy.Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practiceProspective study of low-dose cyclosporine A in patients with refractory lupus nephritis
P2860
Q33654712-304FA17F-CCE1-44C6-9A37-E8CA7C3E7905Q33805271-4E20CE76-0998-4AA2-9099-87AD4B60C164Q34417671-5F034875-4BFA-4667-AA28-2CB28CB7BC97Q35727027-528CB322-A3C5-4E67-A4C5-F57794D187C5Q35824515-05356C20-B64F-4B91-88F1-53D0D2B26BB8Q35918369-8FFAD4EE-7DD3-4301-B6BA-5AD4EF50FB73Q36802101-36A445BF-1119-4964-89E0-C4599C97FE18Q37063971-B6B0837E-BD1B-4A9D-A38A-743D2A798EC4Q37105605-314267CD-269F-4AC2-A036-D28298B1076CQ37312560-4F4CD16B-0D05-4657-8742-1A4B34135770Q37312612-7886D403-FADF-4A74-84EC-1AF400A732ADQ37974990-3585C3E0-4887-4274-96FA-50E553A2952EQ37995966-74C2EF16-C6BB-4686-A647-78F1D560B5F2Q38316279-3FD75591-2C71-420E-8F6D-155C45B42BEAQ38846584-BB432668-76B5-4248-A472-487961A19F70Q39228582-29389FF3-1695-48D7-8DDE-7ED7BCC9A139Q40200817-DA847A74-C2AA-4B5B-9007-50923098B8E0Q40259370-EB3D2557-3AF5-4C00-98D2-3265DAFABE91Q40748681-030C0249-D729-4AB3-B0DB-606DD2DCB542Q42705669-D800B573-1F7F-4E60-B5E1-DB9939C36D81Q43519793-42F89958-FD01-4576-BD15-4A2C8C1751C7Q43805549-D9EA65F6-AE82-42AE-8348-CA901B3F0270Q44098516-56501253-4687-4918-AC59-C9B41B68B79FQ44206742-EFEB1126-5FF4-45C7-B871-88FCCBCDC8E2Q45948300-B3E1DA49-1054-40D7-BC23-5E08163EE56CQ46202538-A234999D-3F56-440E-A384-0C7B218046FDQ46553014-939F5295-B7EB-4ECA-8777-D383C6FB022CQ47105115-6D4FA8B5-405E-4689-9377-60DF777BF848Q48023919-09BE9D68-A3E3-439F-8B12-C5FC954B647DQ50076914-70368314-DA4C-48A3-A8E6-EA435FE0A9C0Q50959012-1CCEDE08-345C-4804-BD0E-E581105D004CQ51173136-3D128EC7-DBF7-4337-8598-077BBA97EEFBQ51573777-FFBB356F-0EAF-45B3-874C-7E6937D3FCF4Q51648740-C092A8F5-BBFC-4F16-920F-5CA4CAA07181Q51743744-3789766F-D0F0-4078-BBD9-44C56A17E2A8Q53013587-6DA7D223-7A30-479E-9CC4-6E0119CF02A0Q53633371-D25A3A33-9093-4883-A39D-5B08ED924670Q58204835-7C12818F-BB5B-4AEE-A2D8-CC40896FBE31Q58204921-DBC5F17A-D106-4D42-8F34-7AC27A6DE1F0
P2860
Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@ast
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@en
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@nl
type
label
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@ast
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@en
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@nl
prefLabel
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@ast
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@en
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@nl
P2860
P356
P1476
Incidence of ovarian failure i ...... t with pulse cyclophosphamide.
@en
P2093
McDermott EM
P2860
P304
P356
10.1136/ARD.55.4.224
P407
P577
1996-04-01T00:00:00Z